Skip to content
sellWeak cluster of 3

Christine Ring sold $47k of NRIX

Chief Legal Officer at Nurix Therapeutics, Inc.. 3,644 shares at an average of $12.80, traded Oct 30, 2025, filed Oct 30, 2025.

Warning score
21
Value
$47k
3,644 shares
Holdings after
50,897
-7% from before
From 52-week low
+55%
low $8.24, close $12.78
From 52-week high
-55%
high $28.14, as of Oct 30, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $47k at market
    +6
  • Share of holdings sold
    Sold 6.7% of holdings
    0
  • Cluster
    3 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

NRIXOct 9, 2026 · close 22.35
Since filing Oct 30, 2025: +74.9%SPY +15.8% · excess +59.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001817199-25-000005, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 30, 2025MOption exercise
Common Stock
+1,924$0.00$045,933Oct 30, 2025
Oct 30, 2025MOption exercise
Common Stock
+2,000$0.00$047,933Oct 30, 2025
Oct 30, 2025MOption exercise
Common Stock
+3,750$0.00$051,683Oct 30, 2025
Oct 30, 2025MOption exercise
Common Stock
+2,858$0.00$054,541Oct 30, 2025
Oct 30, 2025SOpen-market sale
Common Stock
-3,644$12.80$47k50,897Oct 30, 2025
Oct 30, 2025MOption exercise
Restricted Stock Unitsderivative
-1,924$0.00$01,925Oct 30, 2025
Oct 30, 2025MOption exercise
Restricted Stock Unitsderivative
-2,000$0.00$04,000Oct 30, 2025
Oct 30, 2025MOption exercise
Restricted Stock Unitsderivative
-3,750$0.00$022,500Oct 30, 2025
Oct 30, 2025MOption exercise
Restricted Stock Unitsderivative
-2,858$0.00$028,584Oct 30, 2025

Related signals

Other insiders at Nurix Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
1Weak
NRIXsell10b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$134k
5,786 shares
-39%
9Weak
NRIXsell 210b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$149k
5,787 shares
-39%
0Weak
NRIXsell 210b5-1
Nurix Therapeutics, Inc.
Gwenn Hansen
Chief Scientific Officer
$37k
1,452 shares
-1%
11Weak
NRIXsell10b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$126k
8,148 shares
-19%
33Weak
NRIXsell 310b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$238k
14,261 shares
-25%
24Weak
NRIXsell 3
Nurix Therapeutics, Inc.
Gwenn Hansen
Chief Scientific Officer
$81k
4,895 shares
-6%
23Weak
NRIXsell 3
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$73k
4,421 shares
-7%
29Weak
NRIXsell 3
Nurix Therapeutics, Inc.
Hans van Houte
Chief Financial Officer
$61k
3,661 shares
-7%
3Weak
NRIXsell 310b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$69k
3,760 shares
-7%
0Weak
NRIXsell10b5-1
Nurix Therapeutics, Inc.
Christine Ring
Chief Legal Officer
$67k
3,760 shares
-7%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Christine Ring sold $47k of NRIX | InsiderTell